ROCEPHIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Rocephin, and when can generic versions of Rocephin launch?
Rocephin is a drug marketed by Hoffmann La Roche and Roche and is included in five NDAs.
The generic ingredient in ROCEPHIN is ceftriaxone sodium; lidocaine. There are twenty-six drug master file entries for this compound. Additional details are available on the ceftriaxone sodium; lidocaine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ROCEPHIN?
- What are the global sales for ROCEPHIN?
- What is Average Wholesale Price for ROCEPHIN?
Summary for ROCEPHIN
US Patents: | 0 |
Applicants: | 2 |
NDAs: | 5 |
Raw Ingredient (Bulk) Api Vendors: | 45 |
Clinical Trials: | 20 |
Patent Applications: | 5,766 |
Formulation / Manufacturing: | see details |
DailyMed Link: | ROCEPHIN at DailyMed |
![ROCEPHIN drug patent expirations Drug patent expirations by year for ROCEPHIN](/p/graph/s/t/ROCEPHIN-patent-expirations.png)
Recent Clinical Trials for ROCEPHIN
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Samsung Medical Center | Phase 3 |
Tan Tock Seng Hospital | Phase 3 |
National University Hospital, Singapore | Phase 3 |